Avid Bioservices Appoints Kenneth Bilenberg as CEO

Avid Bioservices Inc., a biologics contract development and manufacturing organization (CDMO), has appointed Kenneth Bilenberg as its new Chief Executive Officer (CEO).

A seasoned industry executive with more than 20 years of experience, Bilenberg most recently served as Chief Operating Officer of Fujifilm Biotechnologies, leading large-scale biologics operations. Prior to that, he held senior leadership roles at Novo Nordisk. He is currently based in Denmark and will be relocating to California within the next six months.

He succeeds Nick Green, who is stepping down for health reasons after guiding Avid through a period of strong growth.

“Throughout this process, it was important to me to help identify the right leader to advance Avid into its next chapter,” said Green. “In Kenneth, we found someone with key industry experience as well as a strong vision and a true appreciation for Avid’s culture. I am confident the company is in excellent hands.”

“Few companies stand out the way Avid does for its quality, regulatory track record, and delivery performance — always keeping patients, clients, and people at the center,” said Bilenberg. “It is an honor to join Avid and to contribute to its vision of becoming a global leader in biomanufacturing solutions. Whether enabling predictable pathways from DNA to IND, advancing to BLA and commercial readiness, or supplying therapies at scale, Avid is well-positioned to deliver for clients worldwide.”

Bilenberg’s near-term priorities include:

• Continuing reliable delivery for existing clients
• Supporting global biopharma reshoring and regional supply strategies
• Expanding Avid’s capacity to meet growing worldwide demand

Under Bilenberg’s leadership, Avid aims to build on its foundation, expand its capabilities, and thrive as a trusted partner in advancing biologics to patients worldwide.